109 related articles for article (PubMed ID: 9860924)
1. Molecular basis of P450 inhibition and activation: implications for drug development and drug therapy.
Szklarz GD; Halpert JR
Drug Metab Dispos; 1998 Dec; 26(12):1179-84. PubMed ID: 9860924
[TBL] [Abstract][Full Text] [Related]
2. Analysis of four residues within substrate recognition site 4 of human cytochrome P450 3A4: role in steroid hydroxylase activity and alpha-naphthoflavone stimulation.
Domanski TL; Liu J; Harlow GR; Halpert JR
Arch Biochem Biophys; 1998 Feb; 350(2):223-32. PubMed ID: 9473295
[TBL] [Abstract][Full Text] [Related]
3. Identification of amino acid residues involved in the inactivation of cytochrome P450 2B1 by two acetylenic compounds: the role of three residues in nonsubstrate recognition Sites.
Von Weymarn LB; Sridar C; Hollenberg PF
J Pharmacol Exp Ther; 2004 Oct; 311(1):71-9. PubMed ID: 15178696
[TBL] [Abstract][Full Text] [Related]
4. Dual role of human cytochrome P450 3A4 residue Phe-304 in substrate specificity and cooperativity.
Domanski TL; He YA; Harlow GR; Halpert JR
J Pharmacol Exp Ther; 2000 May; 293(2):585-91. PubMed ID: 10773032
[TBL] [Abstract][Full Text] [Related]
5. Probing ligand binding modes of human cytochrome P450 2J2 by homology modeling, molecular dynamics simulation, and flexible molecular docking.
Li W; Tang Y; Liu H; Cheng J; Zhu W; Jiang H
Proteins; 2008 May; 71(2):938-49. PubMed ID: 18004755
[TBL] [Abstract][Full Text] [Related]
6. Mechanism-based inactivation of cytochrome P450 3A4 by 4-ipomeanol.
Alvarez-Diez TM; Zheng J
Chem Res Toxicol; 2004 Feb; 17(2):150-7. PubMed ID: 14967002
[TBL] [Abstract][Full Text] [Related]
7. Influence of P450 3A4 SRS-2 residues on cooperativity and/or regioselectivity of aflatoxin B(1) oxidation.
Xue L; Wang HF; Wang Q; Szklarz GD; Domanski TL; Halpert JR; Correia MA
Chem Res Toxicol; 2001 May; 14(5):483-91. PubMed ID: 11368545
[TBL] [Abstract][Full Text] [Related]
8. Selective inhibitors of cytochromes P450.
Halpert JR; Guengerich FP; Bend JR; Correia MA
Toxicol Appl Pharmacol; 1994 Apr; 125(2):163-75. PubMed ID: 8171425
[TBL] [Abstract][Full Text] [Related]
9. Analysis of human cytochrome P450 2C8 substrate specificity using a substrate pharmacophore and site-directed mutants.
Melet A; Marques-Soares C; Schoch GA; Macherey AC; Jaouen M; Dansette PM; Sari MA; Johnson EF; Mansuy D
Biochemistry; 2004 Dec; 43(49):15379-92. PubMed ID: 15581350
[TBL] [Abstract][Full Text] [Related]
10. Substrate inhibition kinetics for cytochrome P450-catalyzed reactions.
Lin Y; Lu P; Tang C; Mei Q; Sandig G; Rodrigues AD; Rushmore TH; Shou M
Drug Metab Dispos; 2001 Apr; 29(4 Pt 1):368-74. PubMed ID: 11259318
[TBL] [Abstract][Full Text] [Related]
11. Filling a hole in cytochrome P450 BM3 improves substrate binding and catalytic efficiency.
Huang WC; Westlake AC; Maréchal JD; Joyce MG; Moody PC; Roberts GC
J Mol Biol; 2007 Oct; 373(3):633-51. PubMed ID: 17868686
[TBL] [Abstract][Full Text] [Related]
12. Heterotropic and homotropic cooperativity by a drug-metabolising mutant of cytochrome P450 BM3.
van Vugt-Lussenburg BM; Damsten MC; Maasdijk DM; Vermeulen NP; Commandeur JN
Biochem Biophys Res Commun; 2006 Aug; 346(3):810-8. PubMed ID: 16777067
[TBL] [Abstract][Full Text] [Related]
13. Mechanism of CYP2C9 inhibition by flavones and flavonols.
Si D; Wang Y; Zhou YH; Guo Y; Wang J; Zhou H; Li ZS; Fawcett JP
Drug Metab Dispos; 2009 Mar; 37(3):629-34. PubMed ID: 19074529
[TBL] [Abstract][Full Text] [Related]
14. Site-directed mutagenesis of the putative distal helix of peroxygenase cytochrome P450.
Matsunaga I; Ueda A; Sumimoto T; Ichihara K; Ayata M; Ogura H
Arch Biochem Biophys; 2001 Oct; 394(1):45-53. PubMed ID: 11566026
[TBL] [Abstract][Full Text] [Related]
15. Molecular recognition in (+)-alpha-pinene oxidation by cytochrome P450cam.
Bell SG; Chen X; Sowden RJ; Xu F; Williams JN; Wong LL; Rao Z
J Am Chem Soc; 2003 Jan; 125(3):705-14. PubMed ID: 12526670
[TBL] [Abstract][Full Text] [Related]
16. Evidence that serine 304 is not a key ligand-binding residue in the active site of cytochrome P450 2D6.
Ellis SW; Hayhurst GP; Lightfoot T; Smith G; Harlow J; Rowland-Yeo K; Larsson C; Mahling J; Lim CK; Wolf CR; Blackburn MG; Lennard MS; Tucker GT
Biochem J; 2000 Feb; 345 Pt 3(Pt 3):565-71. PubMed ID: 10642515
[TBL] [Abstract][Full Text] [Related]
17. Mechanism-based inactivation and reversibility: is there a new trend in the inactivation of cytochrome p450 enzymes?
Blobaum AL
Drug Metab Dispos; 2006 Jan; 34(1):1-7. PubMed ID: 16369051
[TBL] [Abstract][Full Text] [Related]
18. Importance of amino acid residue 474 for substrate specificity of canine and human cytochrome p450 3A enzymes.
He YQ; Roussel F; Halpert JR
Arch Biochem Biophys; 2001 May; 389(2):264-70. PubMed ID: 11339816
[TBL] [Abstract][Full Text] [Related]
19. Homotropic cooperativity of monomeric cytochrome P450 3A4 in a nanoscale native bilayer environment.
Baas BJ; Denisov IG; Sligar SG
Arch Biochem Biophys; 2004 Oct; 430(2):218-28. PubMed ID: 15369821
[TBL] [Abstract][Full Text] [Related]
20. Threonine-205 in the F helix of p450 2B1 contributes to androgen 16 beta-hydroxylation activity and mechanism-based inactivation.
Lin HL; Zhang H; Waskell L; Hollenberg PF
J Pharmacol Exp Ther; 2003 Aug; 306(2):744-51. PubMed ID: 12721329
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
